Literature DB >> 33800267

The Role of Extracellular Matrix Components in Inflammatory Bowel Diseases.

Alicja Derkacz1, Paweł Olczyk2, Krystyna Olczyk1, Katarzyna Komosinska-Vassev1.   

Abstract

The remodeling of extracellular matrix (ECM) within the intestine tissues, which simultaneously involves an increased degradation of ECM components and excessive intestinal fibrosis, is a defining trait of the progression of inflammatory bowel diseases (IBDs), which include ulcerative colitis (UC) and Crohn's disease (CD). The increased activity of proteases, especially matrix metalloproteinases (MMPs), leads to excessive degradation of the extracellular matrix and the release of protein and glycoprotein fragments, previously joined with the extracellular matrix, into the circulation. MMPs participate in regulating the functions of the epithelial barrier, the immunological response, and the process of wound healing or intestinal fibrosis. At a later stage of fibrosis during IBD, excessive formation and deposition of the matrix is observed. To assess changes in the extracellular matrix, quantitative measurement of the concentration in the blood of markers dependent on the activity of proteases, involved in the breakdown of extracellular matrix proteins as well as markers indicating the formation of a new ECM, has recently been proposed. This paper describes attempts to use the quantification of ECM components as markers to predict intestinal fibrosis and evaluate the healing process of the gut. The markers which reflect increased ECM degradation, together with the ones which show the process of creating a new matrix during IBD, allow the attainment of important information regarding the changes in the intestinal tissue, epithelial integrity and extracellular matrix remodeling. This paper contains evidence confirming that ECM remodeling is an integral part of directional cell signaling in the progression of IBD, and not only a basis for the ongoing processes.

Entities:  

Keywords:  Crohn’s disease; extracellular matrix components; hyaluronan; inflammatory bowel disease; ulcerative colitis

Year:  2021        PMID: 33800267      PMCID: PMC7962650          DOI: 10.3390/jcm10051122

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  4 in total

Review 1.  Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?

Authors:  Eduardo J Villablanca; Katja Selin; Charlotte R H Hedin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-04-19       Impact factor: 73.082

2.  Gene Expression Meta-Analysis of Potential Shared and Unique Pathways between Autoimmune Diseases under Anti-TNFα Therapy.

Authors:  Charalabos Antonatos; Mariza Panoutsopoulou; Georgios K Georgakilas; Evangelos Evangelou; Yiannis Vasilopoulos
Journal:  Genes (Basel)       Date:  2022-04-27       Impact factor: 4.141

3.  Lupin Protein Concentrate as a Novel Functional Food Additive That Can Reduce Colitis-Induced Inflammation and Oxidative Stress.

Authors:  Joana Mota; Sandra Casimiro; João Fernandes; Renata M Hartmann; Elizângela Schemitt; Jaqueline Picada; Luís Costa; Norma Marroni; Anabela Raymundo; Ana Lima; Ricardo Boavida Ferreira
Journal:  Nutrients       Date:  2022-05-18       Impact factor: 6.706

4.  Visualization of Inflammation in Experimental Colitis by Magnetic Resonance Imaging Using Very Small Superparamagnetic Iron Oxide Particles.

Authors:  Laura Golusda; Anja A Kühl; Malte Lehmann; Katja Dahlke; Susanne Mueller; Philipp Boehm-Sturm; Jessica Saatz; Heike Traub; Joerg Schnorr; Christian Freise; Matthias Taupitz; Karina Biskup; Véronique Blanchard; Oliver Klein; Ingolf Sack; Britta Siegmund; Daniela Paclik
Journal:  Front Physiol       Date:  2022-07-12       Impact factor: 4.755

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.